Summary: The purpose of this study is to evaluate if a VR headset and/or aromatherapy can be used to reduce patient pain, anxiety, and embarrassment during a t...
Summary: The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and fami...
Summary: The investigators hypothesize that this single-cell analysis can be used to evaluate prostate needle-core biopsies prospectively even in non-homogenou...
Summary: This study is being done to determine the acceptance and effectiveness of a virtual robot assistant model at a urology clinic....
Summary: This study evaluates how new magnetic resonance imaging (MRI) and artificial intelligence techniques improve the image quality and quantitative inform...
Summary: The purpose of this study is to see whether using the 64Cu-NOTA-PSMA-PEG-Cy5.5-C' dot tracer is a safe way to identify tumor cells before and during s...
Summary: The purpose of this research is to test intervention strategies that encourage and support Black or African American men who are 40 and older to compl...
Summary: This phase III trial compares the effects of robot-assisted radical prostatectomy (RARP) with or without vesicopexy on urinary continence (a person's ...
Summary: The goal of this observational study is to increase genetic education and genetic testing for hereditary cancer risk among cancer survivors.The stud...
Summary: This study aims to determine if web-based eHealth delivery of pre-test and/or post-test counseling in cancer patients and/or those at risk for cancer ...
Summary: Genetic testing is a type of test that detects changes to the genes-the DNA instructions that are passed on from the mother and father. The results of...
Summary: This study will test the safety of using Illuminare-1 during standard surgery for prostate cancer. The study researchers will test increasing doses of...
Summary: This is a three-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or...
Summary: Prostate cancer (PCa) is the most common non-dermatologic malignancy in U.S. men. Transrectal ultrasound (TRUS)-guided prostate biopsy is a commonly u...
The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The Omaha-004 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC.
VISIT
This clinical trial is for patients who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond to abiraterone acetate or enzalutamide (but not both) and to taxane-based chemotherapy.
VISIT
The primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC) compared to placebo in combination with enzalutamide.
VISITThe primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC), which will be compared to standard treatments alone (either enzalutamide or docetaxel).
VISIT
The LIBERTAS STUDY is researching a way to potentially treat a type of prostate cancer that still responds to hormone therapy. Prostate cancer that spreads to other parts of the body but can still be controlled by interfering with the hormone function of the cancer is called metastatic castration-sensitive prostate cancer (mCSPC).
VISIT
Lorigerlimab is an investigational drug being tested in clinical trials. It is designed to block two checkpoints, telling the immune system cells to wake up and start killing cancer cells. Checkpoint inhibitors, including lorigerlimab, may cause side effects.
VISIT
